Inhibitors of riboflavin biosynthetic pathway enzymes as potential antibacterial drugs

Frontiers in Molecular Biosciences

Molecular Biosciences

Pankaj Kumar¹  Zeyaul Islam² 

[1] Department of Biochemistry, Jamia Hamdard, New Delhi, India;Qatar Biomedical Research Institute (QBRI), Qatar Foundation, Hamad Bin Khalifa University, Doha, Qatar;

关键词: riboflavin biosynthetic pathway;    inhibitors;    3,4-dihydroxy-2-butanone 4-phosphate synthase;    lumazine synthase;    riboflavin synthase;   

DOI  :  10.3389/fmolb.2023.1228763

 received in 2023-05-25, accepted in 2023-07-03,  发布年份 2023

来源: Frontiers

【 摘 要 】

Multiple drug resistance is the main obstacle in the treatment of bacterial diseases. Resistance against antibiotics demands the exploration of new antimicrobial drug targets. A variety of in silico and genetic approaches show that the enzymes of the riboflavin biosynthetic pathway are crucial for the survival of bacteria. This pathway is absent in humans thus enzymes of the riboflavin biosynthetic pathway are emerging drug targets for resistant pathogenic bacterial strains. Exploring the structural details, their mechanism of action, intermediate elucidation, and interaction analysis would help in designing suitable inhibitors of these enzymes. The riboflavin biosynthetic pathway consists of seven distinct enzymes, namely, 3,4-dihydroxy-2-butanone 4-phosphate synthase, GTP cyclohydrolase II, pyrimidine deaminase/reductase, phosphatase, lumazine synthase, and riboflavin synthase. The present review summarizes the research work that has been carried out on these enzymes in terms of their structures, active site architectures, and molecular mechanism of catalysis. This review also walks through small molecule inhibitors that have been developed against several of these enzymes.

【 授权许可】

Unknown   
Copyright © 2023 Islam and Kumar.